NEW YORK (GenomeWeb News) – Prodesse will distribute Cepheid’s SmartCycler System and related products in the US under a new non-exclusive agreement, Milwaukee, Wis.-based Prodesse said today.
Prodesse’s ProFlu+ Assay and three other assays have been cleared by the Food and Drug Administration for use with the SmartCycler, and other tests are in the pipeline, the company said.
"Many of the top 100 hospitals in the country already have moved to molecular detection for influenza," Prodesse President and CEO Tom Shannon said in a statement. "This distribution agreement allows us to better serve clinical lab customers as more and more of them seek to implement products like ProFlu+."
Financial and other terms of the distribution pact were not disclosed.